Takara Bio Inc 2022 IR
The report highlights Takara Bio's performance and sustainability initiatives for the fiscal year ended March 31, 2022. The company achieved record-high financial results, driven by strong demand for PCR-related products and CDMO services. Key sustainability achievements include identifying eight materialities, such as wellness, safety, and climate change, and establishing the Takara Bio Group Basic Policy on Sustainability Management. Additionally, the company expanded its CDMO facilities, including the Center for Gene and Cell Processing II, and continued its focus on developing advanced gene therapies.
Company: Takara Bio Inc
Sector: Health Care
Country: Japan
Year: 2022
Type: IR
Pages: 16
Takara Bio Inc
Corporate Report
The report highlights Takara Bio's performance and sustainability initiatives for the fiscal year ended March 31, 2022. The company achieved record-high financial results, driven by strong demand for PCR-related products and CDMO services. Key sustainability achievements include identifying eight materialities, such as wellness, safety, and climate change, and establishing the Takara Bio Group Basic Policy on Sustainability Management. Additionally, the company expanded its CDMO facilities, including the Center for Gene and Cell Processing II, and continued its focus on developing advanced gene therapies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Published
Aug 24, 2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Women in Management
Employees